Lantern Pharma announced the appointment of David Margrave as Chief Financial Officer and Kishor Gopaldas Bhatia as Chief Scientific Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.07 USD | -3.65% | -2.57% | +41.82% |
29/05 | Transcript : Lantern Pharma Inc. - Special Call | |
24/05 | Lantern Pharma Files $150 Million Mixed Shelf | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.82% | 6.78Cr | |
+43.36% | 5.81TCr | |
-5.31% | 4.05TCr | |
+37.52% | 3.9TCr | |
+14.75% | 2.67TCr | |
-12.56% | 2.66TCr | |
-22.45% | 1.9TCr | |
+0.04% | 1.22TCr | |
+25.12% | 1.2TCr | |
+26.04% | 1.19TCr |
- Stock Market
- Equities
- LTRN Stock
- News Lantern Pharma Inc.
- Lantern Pharma Inc. Announces Executive Changes